EXEL
EXELIXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$70.22
−0.69%Margins
Gross margin
96.3%
EBITDA margin
43.1%
EBIT margin
40.2%
Net margin
35.5%
FCF margin
46.1%
48.3%
Return on equity
35.2%
Return on assets
50.3%
Return on invested capital
1.00x
Asset turnover
$1.2B
Cash from operations
$3.66
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Oct 1, 2026